XML 35 R24.htm IDEA: XBRL DOCUMENT v3.25.2
Collaboration Agreements (Tables)
 6 Months Ended
Jun. 30, 2025
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Schedule Of Cost Sharing Payments And Reimbursements
Cost sharing payments to collaboration partners recorded as expenses in research and development expenses in the Condensed Consolidated Statements of Operations and Comprehensive Loss, and cost sharing reimbursements from collaboration partners recorded as an offset to expense in research and development expenses in the Condensed Consolidated Statements of Operations and Comprehensive Loss are as follows (in thousands):
Three Months Ended June 30,Six Months Ended June 30,
2025202420252024
Takeda Collaboration Agreement:
PTV:PGRN cost sharing (reimbursements)
$(1,439)$(1,138)$(2,935)$(2,338)
ATV:TREM2 cost sharing (reimbursements)(10)(215)(147)(728)
Total Takeda cost sharing (reimbursements)(1)
(1,449)(1,353)(3,082)(3,066)
Biogen Collaboration Agreement: LRRK2 cost sharing payments(2)
4,229 4,440 8,880 9,229 
Net cost sharing payments (reimbursements)$2,780 $3,087 $5,798 $6,163 
_________________________________
(1)Cost sharing reimbursements of $1.4 million and $1.5 million were recorded as a receivable within prepaid expenses and other current assets on the Condensed Consolidated Balance Sheets as of June 30, 2025 and December 31, 2024, respectively.
(2)Cost sharing payments due to Biogen of $4.2 million and $2.5 million were recorded within accounts payable on the Condensed Consolidated Balance Sheets as of June 30, 2025 and December 31, 2024, respectively.